Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Italy Fines Apple €98.6 Million Over App Store Dominance 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
BURLINGTON, Mass., Aug. 01, 2017 -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in two investor conferences.
JJ Pellegrino, Chief Financial Officer, will participate in the Needham MedTech One-on-One Conference on Tuesday, August 8, 2017 at One Federal Street in Boston, MA.
George LeMaitre, Chairman & CEO, is scheduled to present at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10, 2017 at the Intercontinental Hotel in Boston, MA. The Company’s presentation is scheduled to begin at 9:00 AM EDT.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
Contact: LeMaitre Vascular, Inc. Investor Relations Steven Chehames +1-781-425-1659 [email protected]
